Skip to main content
Log in

Benefits of COVID-19 Vaccine AstraZeneca outweigh risks of blood clots

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. EMA. COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets. Internet Document : 18 Mar 2021. Available from: URL: https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots.

  2. WHO. Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on safety signals related to the AstraZeneca COVID-19 vaccine. Internet Document : 19 Mar 2021. Available from: URL: https://www.who.int/news/item/19-03-2021-statement-of-the-who-global-advisory-committee-on-vaccine-safety-(gacvs)-covid-19-subcommittee-on-safety-signals-related-to-the-astrazeneca-covid-19-vaccine.

  3. MHRA. UK regulator confirms that people should continue to receive the COVID-19 vaccine AstraZeneca. Internet Document : 18 Mar 2021. Available from: URL: https://www.gov.uk/government/news/uk-regulator-confirms-that-people-should-continue-to-receive-the-covid-19-vaccine-astrazeneca.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Benefits of COVID-19 Vaccine AstraZeneca outweigh risks of blood clots. Reactions Weekly 1848, 2 (2021). https://doi.org/10.1007/s40278-021-93004-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-93004-3

Navigation